Cost-effectiveness of lanreotide Autogel® in treatment algorithms of acromegaly

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 9, Issue 3, 2009, Pages 223-234

  Biermasz, Nienke R ^a   Roelfsema, Ferdinand ^a   Pereira, Alberto M ^a   Romijn, Johannes A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acromegaly; Costs; Lanreotide Autogel ; Treatment

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR BLOCKING AGENT; GROWTH HORMONE; HORMONE ANTAGONIST; LANREOTIDE AUTOGEL; OCTREOTIDE; PEGVISOMANT; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

ACROMEGALY; ARTICLE; CHOLELITHIASIS; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG ABSORPTION; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RELEASE; DRUG SAFETY; DRUG SELF ADMINISTRATION; GASTROINTESTINAL SYMPTOM; GLUCOSE METABOLISM; HEALTH CARE COST; HEART FUNCTION; HUMAN; LIPOHYPERTROPHY; MORTALITY; QUALITY OF LIFE; SIDE EFFECT; TRANSSPHENOIDAL SURGERY; TREATMENT OUTCOME;

ACROMEGALY; ALGORITHMS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DELAYED-ACTION PREPARATIONS; GELS; HUMANS; NETHERLANDS; PEPTIDES, CYCLIC; SOMATOSTATIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 68649112129     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.09.17     Document Type: Article

References (66)

1. Melmed S. Medical progress: acromegaly. N. Engl. J. Med. 355(24), 2558-2573 (2006).
2. Biermasz NR, Romijn JA, Pereira AM, Roelfsema F. Current pharmacotherapy for acromegaly: a review. Expert Opin. Pharmacother. 6(4), 2393-2405 (2005).
3. Biermasz NR, Dekker FW, Pereira AM et al. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J. Clin. Endocrinol. Metab. 89(6), 2789-2796 (2004).
4. Melmed S, Casanueva F, Cavagnini F et al. Consensus statement: medical management of acromegaly. Eur. J. Endocrinol. 153(6), 737-740 (2005).
5. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr. Rev. 25(1), 102-152 (2004).
6. Pereira AM, van Thiel SW, Lindner JR et al. Increased prevalence of regurgitant valvular heart disease in acromegaly. J. Clin. Endocrinol. Metab. 89(1), 71-75 (2004).
7. Giustina A, Barkan A, Casanueva FF et al. Criteria far cure of acromegaly: a consensus statement. J. Clin. Endocrinol. Metab. 85(2), 526-529 (2000).
8. Melmed S, Colao A, Barkan A et al. Guidelines for acromegaly management: an update. J. Clin. Endocrinol. Metab. (2009) (Epub ahead of print).
9. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP. Mortality in acromegaly: a metaanalysis. J. Clin. Endocrinol. Metab. 93(1), 61-67 (2008).
10. Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur. J. Endocrinol. 152(3), 379-387 (2005).
11. Biermasz NR, van Dulken H, Roelfsema F. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. J. Clin. Endocrinol. Metab. 85(7), 2476-2482 (2000).
12. Biermasz NR, van Dulken H, Roelfsema F. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. J. Clin. Endocrinol. Metab. 85(12), 4596-4602 (2000).
13. Attanasio R, Epaminonda P, Motti E et al. Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study. J. Clin. Endocrinol. Metab. 88(7), 3105-3112 (2003).
14. Castinetti F, Morange I, Dufour H, Regis J, Brue T. Radiotherapy and radiosurgery in acromegaly. Pituitary 12(1), 3-10 (2009).
15. Castinetti F, Taieb D, Kuhn JM et al. Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. J. Clin. Endocrinol. Metab. 90(8), 4483-4488 (2005).
16. Gutt B, Wowra B, Alexandrov R et al. Gamma-knife surgery is effective in normalising plasma insulin-like growth factor I in patients with acromegaly. Exp. Clin. Endocrinol. Diabetes 113(4), 219-224 (2005).
17. Landolt AM, Haller D, Lomax N et al. Stereotactic radiosurgery for recurrent surgically treated acromegaly: comparison with fractionated radiotherapy. J. Neurosurg. 88(6), 1002-1008 (1998).
18. van der Lely AJ, Hutson RK, Trainer PJ et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358(9295), 1754-1759 (2001).
19. Trainer PJ, Drake WM, Katznelson L et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N. Engl. J. Med. 342(16), 1171-1177 (2000).
20. Feenstra J, de Herder WW, ten Have SM et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 365(9471), 1644-1646 (2005).
21. Abs R, Verhelst J, Maiter D et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J. Clin. Endocrinol. Metab. 83(2), 374-378 (1998).
22. Antonijoan RM, Barbanoj MJ, Cordero JA et al. Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers. J. Pharm. Pharmacol. 56(4), 471-476 (2004).
23. Kuhn JM, Legrand A, Ruiz JM, Obach R, De Ronzan J, Thomas F. Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers. Br. J. Clin. Pharmacol. 38(3), 213-219 (1994).
24. Astruc B, Marbach P, Bouterfa H et al. Long-acting octreotide and prolongedrelease lanreotide formulations have different pharmacokinetic profiles. J. Clin. Pharmacol 45(7), 836-844 (2005).
25. Bronstein M, Musolino N, Jallad R et al. Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days. Clin. Endocrinol. (Oxf.) 63(5), 514-519 (2005).
26. Grass P, Marbach P, Bruns C, Lancranjan I. Sandostatin LAR (microencapsulated octreotide acetate) in acromegaly: pharmacokinetic and pharmacodynamic relationships Metabolism 45 (8 Suppl. 1), 27-30 (1996).
27. Caron P. Somatuline® Autogel®, a new formulation of lanreotide for the treatment of acromegalic patients. Ann. Endocrinol. (Paris) 63(2 Pt 3), 2S19-2S24 (2002).
28. van Thiel SW, Romijn JA, Biermasz NR et al. Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. Eur. J. Endocrinol. 150(4), 489-495 (2004).
29. Alexopoulou O, Abrams P, Verhelst J et al. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur. J. Endocrinol. 151(3), 317-324 (2004).
30. Ashwell SG, Bevan JS, Edwards OM et al. The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR. Eur. J. Endocrinol. 150(4), 473-480 (2004).
31. Caron P, Bex M, Cullen DR et al. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel. Clin. Endocrinol. (Oxf.) 60(6), 734-740 (2004).
32. Gutt B, Bidlingmaier M, Kretschmar K, Dieterle C, Steffin B, Schopohl J. Four-year follow-up of acromegalic patients treated with the new long-acting formulation of lanreotide (lanreotide Autogel). Exp. Clin. Endocrinol. Diabetes 113(3), 139-144 (2005).
33. Caron P, Cogne M, Raingeard I, Bex-Bachellerie V, Kuhn JM. Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. Clin. Endocrinol. (Oxf.) 64(2), 209-214 (2006).
34. Lucas T, Astorga R. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a Phase III trial. Clin. Endocrinol. (Oxf.) 65(3), 320-326 (2006).
35. Ronchi CL, Boschetti M, Degli Uberti EC et al. Efficacy of a slow-release formulation of lanreotide (Autogel 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. Clin. Endocrinol. (Oxf.) 67(4), 512-519 (2007).
36. Andries M, Glintborg D, Kvistborg A, Hagen C, Andersen M. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-I in patients with acromegaly. Clin. Endocrinol. (Oxf.) 68(3), 473-480 (2008).
37. Chanson P, Borson-Chazot F, Kuhn JM, Blumberg J, Maisonobe P, Delemer B. Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. Clin. Endocrinol. (Oxf.) 69(2), 299-305 (2008).
38. Attanasio R, Lanzi R, Losa M et al. Effects of lanreotide Autogel on growth hormone, insulinlike growth factor 1, and tumor size in acromegaly: a 1-year prospective multicenter study. Endocr. Pract. 14(7), 846-855 (2008).
39. Melmed S, Sternberg R, Cook D et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin. Endocrinol. Metab. 90(7), 4405-4410 (2005).
40. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 90(8), 4465-4473 (2005).
41. Roelfsema F, Biermasz NR, Pereira AM, and Romijn JA. Therapeutic options in the management of acromegaly: focus on lanreotide Autogel. Biologics: Targets Ther. 2(3), 463-479 (2008)
42. Pereira AM, Biermasz NR, Roelfsema F, Romijn JA. Pharmacologic therapies for acromegaly: a review of their effects on glucose metabolism and insulin resistance. Treat. Endocrinol. 4(1), 43-53 (2005).
43. Steffin B, Gutt B, Bidlingmaier M, Dieterle C, Oltmann F, Schopohl J. Effects of the long-acting somatostatin analogue lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly. Eur. J Endocrinol. 155(1), 73-78 (2006).
44. Ertorer ME, Bakiner O, Anaforoglu I, Bozkirli E, Tutuncu NB, Demirag NG. Lanreotide autogel and insulin sensitivity markers: report of 5 acromegalic patients and literature review. Neuro. Endocrinol. Lett. 28(6), 727-733 (2007).
45. Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A. Effects of somatostatin analogs on glucose homeostasis: a meta-analysis of acromegaly studies. J. Clin. Endocrinol. Metab. (2009) (Epub ahead of print).
46. Colao A, Marek J, Goth MI et al. No greater incidence or worsening of cardiac valve regurgitation with somatostatin analog treatment of acromegaly. J. Clin. Endocrinol. Metab. 93(6), 2243-2248 (2008).
47. Trepp R, Everts; R, Stettler C et al. Assessment of quality of life in patients with uncontrolled vs. controlled acromegaly using the Acromegaly Quality of Life Questionnaire (AcroQoL). Clin. Endocrinol. (Oxf) 63 (1), 103-110 (2005).
48. Paisley AN, Rowles SV, Roberts ME et al. Treatment of acromegaly improves quality of life, measured by AcroQol. Clin. Endocrinol. (Oxf.) 67(3), 358-362 (2007).
49. Matta MP, Couture E, Cazals L, Vezzosi D, Bennet A, Caron P. Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance. Eur. J. Endocrinol. 158(3), 305-310 (2008).
50. Rowles SV, Prieto L, Badia X, Shalet SM, Webb SM, Trainer PJ. Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire. J. Clin. Endocrinol. Metab. 90(6), 3337-3341 (2005).
51. Hua SC, Yan YH, Chang TC. Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly. Eur. J. Endocrinol. 155 (6), 831-837 (2006).
52. Neggers SJ, van Aken MO, Janssen JA, Feelders RA, de Herder WW, van der Lely AJ. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J. Clin. Endocrinol. Metab. 92(12), 4598-4601 (2007).
53. Neggers; SJ, van Aken MO, de Herder WW et al. Quality of I ife in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J. Clin. Endocrinol. Metab. 93(10), 3853-3859 (2008).
54. Caron P, Beckers A, Cullen DR et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J. Clin. Endocrinol. Metab. 87(1), 99-104 (2002).
55. van Thiel SW, Romijn JA, Biermasz NR et al. Octreodde long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. Eur. J Endocrinol. 150(4), 489-495 (2004).
56. Didoni G, Grottol S, Gasco V et al. Cost-of-illness study in acromegalic patients in Italy. J. Endocrinol. Invest. 27(11), 1034-1039 (2004).
57. Luque-Ramirez; M, Paramo C, Varela DC, Garcia-Mayor RV. Cost of management of invasive growth hormone-secreting macroadenoma. J. Endocrinol. Invest. 30(7), 541-545 (2007).
58. Wilson LS, Shin JL, Ezzat S. Longitudinal assessment of economic burden and clinical outcomes in acromegaly. Endocr. Pract. 7(3), 170-180 (2001).
59. Knutzen R, Ezzat S. The cost of medical care for the acromegalic patient. Neuroendocrinology 83 (3-4), 139-144 (2006).
60. Valentim J, Passos V, Mataveli F, Calabro A. Cost-effectiveness analysis of somatostatin analogues in the treatment of acromegaly in Brazil. Arq. Bras. Endocrinol. Metabol. 52(9), 1452-1460 (2008).
61. Biermasz NR, van den Oever NC, Frolich M et al. Sanclostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval. Clin Endocrinol (Oxf.) 58(3), 288-295 (2003).
62. Turner HE, Thornton-Jones VA, Wass JA. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly. Clin. Endocrinol. (Oxf.) 61(2), 224-231 (2004).
63. Abrams P, Alexopoulou O, Abs R, Maiter D, Verhelst J. Optimalization and cost management of lanreotide-Autogel therapy in acromegaly. Eur. J. Endocrinol. 157(5), 571-577 (2007).
64. Bevan JS, Newell-Price J, Wass JA et al. Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective. Clin. Endocrinol. (Oxf.) 68(3), 343-349 (2008).
65. Ronchi CL, Rizzo E, Lania AG et al. Preliminary data on biochemical remission of acromegaly after somatostatin analogs withdrawal. Eur. I Endocrinol. 158 (1), 19-25 (2008).
66. van der Klaauw AA, Biermasz NR, Hoftijzer HC, Pereira AM, Rornijn JA. Previous radiotherapy negatively influences quality of life during 4 years of follow-up in patients cured from acromegaly. Clin Endocrinol (Oxf.) 69 (1), 123-128 (2008).